Health Canada provides an overview of natural health products linked with rare cases of hepatotoxicity and how to counsel patients about this potential risk.
Study compares cardiovascular outcomes of weekly tirzepatide versus dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease.